Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402688 | 1.00 | CYP2C9 (0.48) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6403990 | 1.00 | CYP2C9 (0.48) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6405409 | 0.79 | CTSK (0.44) | FFAR2CTSKTSHRPKM | |
| SCHEMBL6406303 | 0.79 | HTT (0.46) | CTSKALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6404507 | 0.79 | HTT (0.46) | CTSKALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6403780 | 0.79 | CTSK (0.44) | FFAR2CTSKTSHRPKM | |
| SCHEMBL6406194 | 0.79 | CTSK (0.44) | FFAR2CTSKTSHRPKM | |
| SCHEMBL27842938 | 0.73 | CYP2C9 (0.56) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6406277 | 0.71 | CTSK (0.43) | CTSKLMNATSHR | |
| SCHEMBL6403133 | 0.71 | CTSK (0.43) | CTSKLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CYP2C9 2459/4885CYP1A2 1519/4885CYP3A4 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.